Merck receives CHMP opinion recommending approval of Keytruda
Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...
Business Insider14d
Merck & Co.: Hold Rating Amid Declining Gardasil Shipments and Inventory Challenges
In a report released yesterday, Mohit Bansal from Wells Fargo assigned a Hold rating on Merck & Company (MRK – Research Report), with a price target of $110.00. Mohit Bansal has given his Hold ...
pharmaphorum14d
Merck gets FDA okay for Keytruda as liver cancer therapy
Merck & Co/MSD has won approval in the US for ... Tyrosine kinase inhibitor (TKI) Nexavar has been the mainstay of first-line HCC therapy for years, but prognosis for patients continues to be ...
Investing17d
Merck and Moderna launch phase 3 trial for lung cancer therapy
The information provided here does not include promotional content or endorsements of the therapy's effectiveness, as its success will depend on the outcomes of the ongoing trial. Merck and Moderna ...
Seeking Alpha21d
Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
Some are leveraging Merck's partnership with Daiichi Sankyo to develop antibody drug conjugates ("ADCs"), a pioneering new type of dual action therapy (two candidates to date - ifinatamab ...
Morningstar21d
BetterInvesting™ Magazine Update on Merck (MRK) and Ball (BALL)
TROY, Mich., Oct. 25, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Merck & Co. (NYSE: MRK) as its "Stock to Study" and ...